TABLE 1

Risk Factors for Developing Cholestasis Among Infants Receiving FP

Cholestasis (N = 127)No Cholestasis (N = 282)P
Gestation, median (range), wk26 (23–32)26 (23–30.9).122
BW, median (range), g691 (375–1290)813 (310–1460)<.001
Use of fluconazole
    Age at last dose, median (range), d42 (5–47)25 (1–45)<.001
    No. of doses, median (range)25 (2–26)11 (1–26)<.001
Necrotizing enterocolitis, n (%)57 (45)34 (12)<.001
TPN, n (%)126 (99)279 (99).99
Duration of TPN, median (range), d53 (7–361)24 (1–96)<.001
H2 receptor blockers, n (%)117 (92)237 (84).028
Metoclopramide, n (%)84 (66)165 (59).156
Proton pump inhibitors, n (%)10 (8)27 (10).71
Antimicrobial agents, n (%)
    Ampicillin126 (99)260 (92).002
    Cefotaxime60 (47)80 (28)<.001
    Ceftazidime10 (8)8 (2.8).034
    Ceftriaxone1 (0.8)1 (0.4).525
    Clindamycin62 (49)55 (19)<.001
    Gentamicin124 (98)269 (95).41
    Meropenem3 (2.4)2 (0.7).176
    Nafcillin33 (26)35 (12).001
    Penicillin1 (0.8)3 (1.1).99
    Piperacillin-tazobactam2 (1.6)1 (0.4).229
    Rifampin7 (5.5)6 (2.1).122
    Timentin2 (1.6)1 (0.4).229
    Vancomycin124 (98)207 (73)<.001
  • The Mann-Whitney U test was used for median values.